Phoenix, AZ (PRWEB) September 10, 2010
A recent European clinical trial provided significant evidence for the effectiveness of using targeted heat therapy, or hyperthermia, in cancer treatment. The trial's findings support the use of hyperthermia in cancer treatment, but the news of the trial's success came as no surprise to the doctors at the EuroMed Foundation (http://www.euro-med.us), an Arizona cancer center that is continuing to use hyperthermia as one of several cancer treatments for patients.
Robert Zieve, MD at the EuroMed Foundation says that the new research is in line with the outcomes he has seen. "We've found that targeted heat therapy, or hyperthermia, can be a very effective tool for increasing the effectiveness of cancer treatments like our low-dose chemotherapy," he explains.
The recent clinical trial showed a significant difference in the median time patients survived. The group who only received chemotherapy had a median survival time of 18 months, while the group who had hyperthermia in addition to chemotherapy had a median survival time of 32 months. While the difference is significant, more trials need to be completed to determine if there is a difference in overall survival rate.
"Based on these results, what we can say is that hyperthermia is a promising alternative cancer treatment that is extending patients lives," notes Dr. Zieve. "We use hyperthermia in conjunction with an effective low-dose potentiated and targeted chemotherapy known as IPT, or Insulin Potentiation Therapy. With the addition of the hyperthermia treatment, we've found that the effectiveness of IPT increases."
Insulin Potentiation Therapy is an alternative cancer treatment that uses the hormone insulin to target and potentiate very low dose chemotherapy, usually only 10% of the standard dosage. Cancer cells are more susceptible to ingesting chemotherapy drugs when insulin is present, based on the fact that cancer cells have more insulin receptors to sustain their rampant growth. Insulin works by lowering blood sugar, putting high metabolic cancer cells in a vulnerable environment, which means a very low dose of chemotherapy is required. And with the addition of hyperthermia, the physicians at the EuroMed Foundation can provide a more comprehensive treatment.
"We combined the procedure with IPT based on this powerful combination for targeting cancer cells," Dr. Zieve says. "Hyperthermia works by targeting heat on cancerous tumors, causing the cancer cells to over-metabolize and rupture, while ideally protecting normal cells with added heat shock proteins. If we can target the cancer cells better, that means we can administer the lowest possible dose of chemotherapy to the patient and not suppress immune function."
Lower doses, according to Dr. Zieve, provide for a better quality of life since patients rarely experience the debilitating side effects of chemotherapy. "It's always been said that the treatment is worse than the disease with cancer," adds Dr. Zieve, "but we aim to change that by finding alternative treatments that are still very effective while preserving the patient's immune system in the process. I'm encouraged by the recent findings about hyperthermia and hope more research is completed in the coming years."
The EuroMed Foundation (http://www.euro-med.us) is a Phoenix, Arizona cancer center specializing in the detection, diagnosis, and treatment of cancer utilizing the best of conventional and alternative therapies from around the world. The doctors on staff are all highly trained in alternative cancer therapies including Insulin Potentiation Therapy, Hyperthermia, Homeopathic Immune Modulatoin, Ozone Steam Sauna Therapy and many others.